Endometriosis Biomarker Discovery Study
WithdrawnNCT03272360
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is a prospective, Single time point, discovery study intending to identify biomarkers that can differentiate endometriosis from other underlying reasons for pelvic pain. Patients undergoing laparoscopy for evaluation of chronic pelvic pain or elective tubal ligation will be enrolled for collection of tissue samples at the time of laparoscopy.
Study details
- Official title
- A Prospective Sample Collection Study in Patients With Pelvic Pain Undergoing Laparoscopy for Biomarker Identification in Endometriosis
- Conditions
- Sponsor
- Myriad Genetic Laboratories, Inc.
- Start date
- 2016-09
- Primary completion
- 2017-06
- Sex
- Female
- Age range
- from 18 Years to 45 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Able to give informed consent. 2. Aged 18-45 years old who has a regular menstrual cycle (26 to 32 days in length). 3. Undergoing a planned diagnostic or therapeutic laparoscopy for the indication of pelvic pain or for elective tubal ligation. 4. One prior pregnancy for tubal ligation patients. Exclusion Criteria: 1. Prior surgical diagnosis of endometriosis. 2. Currently pregnant or breastfeeding. 3. Clinical suspicion of pelvic inflammatory disease (PID) or urinary tract infection. 4. Current malignancy except non-melanoma skin cancer adequately treated. 5. Known major systemic disease, including but not limited to inflammatory disease, autoimmune disease. 6. Use of immunosuppressants in the past 3 months. 7. Use of injectable reproductive hormonal therapy within the past 3 months and have not menstruated since last dose. 8. If reproductive hormonal implant has been used in the past, it must have been removed \> 3 months prior to study entry and subject must have menstruated since removal. 9. Use of intrauterine device (IUD) in the past 3 months. 10. Use of any other reproductive hormone therapy within the past 3 months, except for oral contraceptives (OCPs).
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03272360